Human trials could start soon on Adam’s 3D printed bone grafts

By

Adam — a young company with technology to 3D print bone grafts made out of ceramic bioglass and modified biopolymer — said today that it expects first human trials to start by the end of the year.

Officials at the Groton, Conn.– and Odessa, Ukraine–based company expect preclinical trials to finish this month. The Adam technology uses Kwambio printers and reduces the standard production cost of synthetic bones in half, from $0.12–$0.15/cm2 down to just $0.08.

Ideally, the bone graft dissolves as new bone grows, reducing the need for additional surgery, according to Adam.

If you want to read more about this news, click here. 

 

Posted in News, Science, Technology.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    21 febrero, 2020

    COFEPRIS Challenges 2020

    Since December 1st, 2018 a historical change in administration that consisted of a new president who is committed to Public Office cleansing of corrupt and unequal practices had a strong impact on the whole country course of operation. Many institutions were eliminated or were audited and restructured.  Cofepris was audited and analyzed for permanence or …

  •
    10 octubre, 2019

    Study: Abbott, Edwards may have mislabeled hundreds of patient deaths

    Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) may have mislabeled patient deaths as injuries or device malfunctions in hundreds of FDA adverse event reports involving their transcatheter aortic or mitral valve replacement devices, according to a new study. The study by JAMA Internal Medicine editor Dr. Rita Redberg, former FDA unique device identification (UDI) external program manager Madris Tomes and others examined a total …

  •
    30 diciembre, 2019

    Finding a non-invasive way to predict effectiveness of cancer therapy.

    «Researchers have taken a critical step toward developing a non-invasive nuclear medicine technique that can predict the effectiveness of therapy for cancerous tumors, allowing for personalized, precision treatment.» Read more.  

  •
    24 agosto, 2020

    COFEPRIS Evolves